$39.210
-0.651 (-1.66%)At close
HRMY News
HRMY Events
Harmony Biosciences Reports Q2 Revenue of $261.28M
Reports Q2 revenue $261.28M, consensus $253.27M. "Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year. With this strong foundation, we are aggressively advancing our pipeline, with our orexin-2 agonist BP-205 as the centerpiece, that we believe can create significant long-term value for both patients and shareholders," said Jeffrey M. Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. "The Phase 1 clinical PK and safety/tolerability data for BP-205 that we shared today, together with pre-clinical data demonstrating the highest potency of any orexin-2 agonist currently in the clinic, reinforce our conviction that BP-205 has the potential to be the best-in-class orexin-2 agonist with broad clinical utility across multiple CNS indications."
Harmony CFO Glenn Reicin Resigns, Stephen Mollichella Appointed Interim
Harmony also announced that its Chief Financial Officer, Glenn Reicin, has stepped down to pursue other opportunities, effective July 16, 2026. The Company appointed Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer, ensuring continuity in the Company's financial leadership as it conducts its search for a permanent CFO. Reicin's departure is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices, and Harmony does not expect this transition to affect its performance or momentum in any way.
Harmony Reiterates 2026 Net Product Revenue Guidance of $1.0 to $1.04 Billion
Based on its first-half performance and current business trends, Harmony is reiterating its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.
Harmony Biosciences Expects Full-Year Net Revenue of $1.0 to $1.04 Billion
"Our record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business," said Jeffrey Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion."
Harmony Biosciences Q1 Revenue $215.39M, Below Expectations
Reports Q1 revenue $215.39M, consensus $220.84M. "Harmony is well positioned for long-term growth, and we are focused on four key pillars to drive value creation. First, protect the pitolisant franchise to ensure durability into the 2030s, supported by multi-layered intellectual property. Second, continued growth of the pitolisant franchise in an evolving market by advancing new formulations and differentiated approaches to solidify our leadership in the sleep/wake market. Third, drive value from our pipeline, led by BP-205, which has the potential to be a highly differentiated and best-in-class orexin-2 agonist across multiple indications. And fourth, a renewed emphasis on business development with a goal to transact on opportunities with revenue potential in the 2028-2032 timeframe," said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "Executing on these four pillars positions us well to deliver innovative treatments for patients and generate long-term value for shareholders."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.